Introducing AGAcell®
The first pre-clinical research program exploring an allogeneic therapy with mesenchymal stem cells for androgenetic alopecia (AGA)
AGAcell® is an investigational pre-clinical cell-therapy program that explores the capacity to restore the cellular niche of the hair follicle, to promote long-term hair growth through a minimally invasive, non-surgical procedure. It is the first preclinical program based on an allogeneic therapy from isolated and expanded mesenchymal stem cells specifically for the treatment of androgenetic alopecia.
The background: Why do we need additional treatment options for alopecia
Androgenetic alopecia (AGA) is a condition that leads to progressive hair loss in millions of men and women worldwide. As one of the most common causes of hair loss, it represents one of the largest segments in the global hair health market.
There are mainly two ways of treating androgenetic alopecia: pharmacological treatments and surgical hair transplants. Below is an overview of the most important significant therapeutic options, and highlights key considerations that might limit their effectiveness and overall use.
Pharmacological treatments
Physical treatments
New treatments
AGAcell®:
An investigacional approach of alopecia treatment
AGAcell® is a patented formulation that combines allogeneic mesenchymal stem cells with a bioactive molecule intended to enhance their regenerative potential. Current pre-clinical studies are examining whether this synergy can modulate the follicular micro-environment and help counteract damage associated with hair-loss progression. Exploratory data in animal models have yielded encouraging results, supporting its further evaluation in human trials.
“AGAcell® is in the pre-clinical stage with ongoing development toward future clinical application.”
The source
The patented formulation
The administration
The benefits
AGAcell®’s advantages vs an autologous therapy
As a potential allogeneic therapy, AGAcell® is based on mesenchymal stem cells sourced from a qualified donor and stored in a cell bank. Unlike autologous procedures, where cells are harvested from, and later re-administered to, the same patient, an allogeneic strategy may offer several practical advantages:
High cell quality
Affordable
More comfortable
Faster
